📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials. (2025)

First Author: White RG

Attributed to: EPCC Tier 2 HPC Service funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2213-2600(25)00164-x

PubMed Identifier: 40618773

Publication URI: http://europepmc.org/abstract/MED/40618773

Type: Journal Article/Review

Volume: 13

Parent Publication: The Lancet. Respiratory medicine

Issue: 10

ISSN: 2213-2600